Are you Dr. DeVore?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 49 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
9700 Tunbridge LN
Knoxville, TN 37922Phone+1 865-599-5543Fax+1 865-934-5801- Is this information wrong?
Summary
- Dr. Russell DeVore III, MD is an oncologist in Knoxville, Tennessee. He is currently licensed to practice medicine in Tennessee, Kentucky, and North Carolina. He is affiliated with Fort Sanders Regional Medical Center and Sweetwater Hospital.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990
Wake Forest University School of MedicineResidency, Internal Medicine, 1984 - 1987
West Virginia University School of MedicineClass of 1984
Certifications & Licensure
TN State Medical License 1987 - 2022
KY State Medical License 2000 - 2019
NC State Medical License 1985 - 1988- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09
- Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2013 Oct 01
- Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Publications & Presentations
PubMed
- 26 citationsPhase II trial of sorafenib and erlotinib in advanced pancreatic cancer.Dana Backlund Cardin, Laura W. Goff, Chung I. Li, Yu Shyr, Charles Winkler, Russell F. DeVore, Larry Schlabach, Melanie Holloway, Pam McClanahan, Krista Meyer, Julia G...> ;Cancer Medicine. 2014 Jun 1
- 5 citationsA Phase II Study of Carboplatin and Irinotecan in Extensive Stage Small-Cell Lung CancerLeora Horn, Zhiguo Zhao, Alan Sandler, David P. Johnson, Yu Shyr, Steven N. Wolff, Russell F. DeVore, Janessa Laskin> ;Clinical Lung Cancer. 2011 May 1
- 62 citationsPhase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancerJohn V. Heymach, David H. Johnson, Fadlo R. Khuri, Howard Safran, L. L. Schlabach, F. Yunus, Russell F. DeVore, P. M. De Porre, H. M. Richards, X. Jia, Steven Zhang, B...> ;Annals of Oncology. 2004 Aug 1
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Fort Sanders Regional Medical CenterKnoxville, Tennessee- Sweetwater HospitalSweetwater, Tennessee
